NN 9709
Alternative Names: NN9709Latest Information Update: 05 Nov 2023
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Mar 2019 Discontinued - Phase-II for Type 2 diabetes mellitus in Denmark (unspecified route)
- 17 Feb 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route) prior to February 2016 (Novo Nordisk's pipeline, February 2016 )